Applied Clinical Trials-10-01-2014

The rush is on to develop new therapies and vaccines to combat the lethal outbreak.

Research shows that the potential of integrated alliances remains elusive in the near term.

The technology necessary to meet the expected regulatory demands for assessing drug-impaired driving has emerged.

Reshuffling to heavily impact life sciences policy in Europe.

A Medical Technology Working Party is established to promote collaboration and dialogue on the specific aspects of clinical standards.

Exploring sourcing model options for appropriate incorporation of DMCs into a clinical program.

The distribution of locations for all trials registered on ClinicalTrials.gov.

S

Proving a biosimilar's pharmacokinetic 'equivalence' requires adherence to several unique factors.

A systematic approach for early identification of BP effects during development of new drugs.

Trial Design: Identify Blood Pressure Effects Early Demonstrating Biosimilarity CRO/Sponsor: Data Monitoring Committee Users Guide Also in this issue: EU Reshuffling Impacts Pharma "Open Integration" Promise Elusive Assessing Drug-Impaired Driving